Table 1.
Ligands/antibodies that are used for lymphatic targeting
| Immune cell/tissue targeting | Ligands/antibodies | Delivery system/payload | Target sites | A.R | Application | Ref |
|---|---|---|---|---|---|---|
| LEC | HA | Polymeric NP | LYVE-1 | / | / | [49] |
| TL | LyP-1 | PEG-PLGA NP | P32 | s.c | Lymphatic metastatic tumors | [50] |
| TL | LyP-1 | Liposome | P32 | s.c | Lymphatic metastatic tumors | [51] |
| Macrophage | HA | HA-PEI/miR-125b | CD44 | i.p | Anticancer immunotherapy | [36] |
| Macrophage | HA | HA-PEI/miR-223 | CD44 | / | Re-polarization of peritoneal macrophages | [57] |
| DC | Mannose | Chitosan NPs/TCL | CD206 | s.c | Cancer vaccine | [56] |
| DC | Galactose | GDR nanogel/OVA | MGL | i.p | Cancer vaccine | [59] |
| DC | R4F | HPPS/Ap and CpG | SR-B1 | s.c | Cancer vaccine | [67] |
| DC | Anti-DEC-205 | Ferrous NPs/CpG and OVA | CD205 | i.v | Antitumor immunotherapy | [37] |
| HEV | MECA79 | Polymeric NP/anti-CD3 | PNAd | i.v | Immune therapy in transplantation | [78] |
| HEV | MECA79 | Polymeric NP/tacrolimus | PNAd | i.v | Immune therapy in transplantation | [79] |
| TAM | M2pep-R4F | HPPS/siRNA | M2/SR-B1 | i.v | Antitumor immunotherapy | [89] |
| SLN | HA /R4F | HPPS/DiR-BOA | CD44/SR-B1 | i.d | Diagnosis of LN metastases | [100] |